DERMATA THERAPEUTICS INC (DRMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.21-3.20%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Dermata is advancing its lead acne drug DMT310 through clinical trials. The company recently beat earnings twice despite losses. It raised $100 million in revenue estimates for 2026, showing growth potential.
Dermata remains loss-making with negative EPS of -2.21 in 2026. Management is volatile with recent officer departures and accounting changes. Revenue estimates fell from $1 million to $750,000 in 2027, signaling weak demand.
The market currently prices Dermata as a clinical-stage biotech with no positive EPS expected through 2027. Our view differs by focusing on the uncertain turnaround progress and volatile management.
Breaks if: Failure to meet key clinical or regulatory milestones by FY26
Breaks if: EPS worsens or remains below -2.21 in FY26 or below -1.52 in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as DRMA is trying to transition into commercial revenue generation. The current thesis state is cautious, given recent earnings misses and a volatile management track record.
The market seems to have priced in a significant level of uncertainty, particularly regarding future earnings and cash management. DRMA's current valuation reflects its loss-making status and the elevated risk associated with its operations.
Fundamentals may continue to struggle in the near term, as evidenced by rising operating losses and cash burn. Management's ability to launch new products and manage costs will be critical for future performance.
The long-term thesis hinges on several factors, including the successful launch of the Foundational Treatment and the performance of key sector peers. Additionally, any guidance cuts or worsening economic indicators could negatively impact DRMA's outlook.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Annual revenue falls below $100 million in FY26 or $750 million in FY27
In the next 1 to 3 years, DRMA's path will depend on its execution of strategic priorities and external market conditions. Not investment advice.